Institutional investors purchased a net $3.2 million shares of CASC during the quarter ended December 2016, and now own 35.25% of the total float, a percentage that is typical for companies in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BVF PARTNERS LP Bought 2.9 Million shares of Cascadian Therapeutics In...